Kyoungbun Lee, Eun Sun Jung, Eunsil Yu, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Woo Sung Moon, Jin Sook Jeong, Cheol Keun Park, Jae-Bok Park, Dae Young Kang, Jin Hee Sohn, So-Young Jin
J Pathol Transl Med. 2020;54(3):228-236. Published online April 15, 2020
Background Liver biopsy is the essential method to diagnose non-alcoholic steatohepatitis (NASH), but histological features of NASH are too subjective to achieve reproducible diagnoses in early stages of disease. We aimed to identify the key histological features of NASH and devise a scoring model for diagnosis.
Methods Thirteen pathologists blindly assessed 12 histological factors and final histological diagnoses (‘not-NASH,’ ‘borderline,’ and ‘NASH’) of 31 liver biopsies that were diagnosed as non-alcoholic fatty liver disease (NAFLD) or NASH before and after consensus. The main histological parameters to diagnose NASH were selected based on histological diagnoses and the diagnostic accuracy and agreement of 12 scoring models were compared for final diagnosis and the NAFLD Activity Score (NAS) system.
Results Inter-observer agreement of final diagnosis was fair (κ = 0.25) before consensus and slightly improved after consensus (κ = 0.33). Steatosis at more than 5% was the essential parameter for diagnosis. Major diagnostic factors for diagnosis were fibrosis except 1C grade and presence of ballooned cells. Minor diagnostic factors were lobular inflammation ( ≥ 2 foci/ × 200 field), microgranuloma, and glycogenated nuclei. All 12 models showed higher inter-observer agreement rates than NAS and post-consensus diagnosis (κ = 0.52–0.69 vs. 0.33). Considering the reproducibility of factors and practicability of the model, summation of the scores of major (× 2) and minor factors may be used for the practical diagnosis of NASH.
Conclusions A scoring system for the diagnosis of NAFLD would be helpful as guidelines for pathologists and clinicians by improving the reproducibility of histological diagnosis of NAFLD.
Citations
Citations to this article as recorded by
Presurgery health influences outcomes following vertical sleeve gastrectomy in adolescents Debi Swertfeger, Ahlee Kim, Hannah Sexmith, Maria E. Moreno‐Fernandez, W. Sean Davidson, Michael Helmrath, Todd Jenkins, Tsuyoshi Okura, Esmond Geh, Stavra A. Xanthakos, Sara Szabo, Takahisa Nakamura, Senad Divanovic, Amy Sanghavi Shah Obesity.2024; 32(6): 1187. CrossRef
Immunobiotic Bacteria Attenuate Hepatic Fibrosis through the Modulation of Gut Microbiota and the Activation of Aryl‐Hydrocarbon Receptors Pathway in Non‐Alcoholic Steatohepatitis Mice Paulraj Kanmani, Julio Villena, Soo‐kyoung Lim, Eun‐Ji Song, Young‐Do Nam, Hojun Kim Molecular Nutrition & Food Research.2024;[Epub] CrossRef
Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease Yifu Lyu, Xiuyi Yang, Lei Yang, Jinyu Dai, Huanyu Qin, Yunuo Zhou, Yunan Huang, Yanmei Wang, Di Wu, Qindai Shuai, Qilong Li, Xiaofei Xin, Lifang Yin Journal of Controlled Release.2024; 373: 385. CrossRef
Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways Wesam F. Farrash, Shakir Idris, Mohamed E. Elzubier, Elshiekh B. A. Khidir, Akhmed Aslam, Abdulrahman Mujalli, Riyad A. Almaimani, Ahmad A. Obaid, Mahmoud Z. El‐Readi, Mohammad A. Alobaidy, Afnan Salaka, Afnan M. Shakoori, Alaa M. Saleh, Faisal Minshawi, International Journal of Experimental Pathology.2024; 105(6): 219. CrossRef
Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease Marlone Cunha-Silva, Luíza D. Torres, Mariana F. Fernandes, Tirzah de M. Lopes Secundo, Marina C.G. Moreira, Ademar Yamanaka, Leonardo T. Monici, Larissa B. Eloy da Costa, Daniel F. Mazo, Tiago Sevá-Pereira Gastroenterología y Hepatología.2022; 45(8): 579. CrossRef
Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease Marlone Cunha-Silva, Luíza D. Torres, Mariana F. Fernandes, Tirzah de M. Lopes Secundo, Marina C.G. Moreira, Ademar Yamanaka, Leonardo T. Monici, Larissa B. Eloy da Costa, Daniel F. Mazo, Tiago Sevá-Pereira Gastroenterología y Hepatología (English Edition).2022; 45(8): 579. CrossRef
Eun Sun Jung, Kyoungbun Lee, Eunsil Yu, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Woo Sung Moon, Jin Sook Jeong, Cheol Keun Park, Jae-Bok Park, Dae Young Kang, Jin Hee Sohn, So-Young Jin
J Pathol Transl Med. 2016;50(3):190-196. Published online April 18, 2016
Background The histomorphologic criteria for the pathological features of liver tissue from patients with non-alcoholic fatty liver disease (NAFLD) remain subjective, causing confusion among pathologists and clinicians. In this report, we studied interobserver agreement of NAFLD pathologic features and analyzed causes of disagreement.
Methods Thirty-one cases of clinicopathologically diagnosed NAFLD from 10 hospitals were selected. One hematoxylin and eosin and one Masson’s trichrome-stained virtual slide from each case were blindly reviewed with regard to 12 histological parameters by 13 pathologists in a gastrointestinal study group of the Korean Society of Pathologists. After the first review, we analyzed the causes of disagreement and defined detailed morphological criteria. The glass slides from each case were reviewed a second time after a consensus meeting. The degree of interobserver agreement was determined by multi-rater kappa statistics.
Results Kappa values of the first review ranged from 0.0091–0.7618. Acidophilic bodies (k = 0.7618) and portal inflammation (k = 0.5914) showed high levels of agreement, whereas microgranuloma (k = 0.0984) and microvesicular fatty change (k = 0.0091) showed low levels of agreement. After the second review, the kappa values of the four major pathological features increased from 0.3830 to 0.5638 for steatosis grade, from 0.1398 to 0.2815 for lobular inflammation, from 0.1923 to 0.3362 for ballooning degeneration, and from 0.3303 to 0.4664 for fibrosis.
Conclusions More detailed histomorphological criteria must be defined for correct diagnosis and high interobserver agreement of NAFLD.
Citations
Citations to this article as recorded by
Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis Vlad Ratziu, Sven Francque, Cynthia A. Behling, Vanja Cejvanovic, Helena Cortez-Pinto, Janani S. Iyer, Niels Krarup, Quang Le, Anne-Sophie Sejling, Dina Tiniakos, Stephen A. Harrison Hepatology.2024; 80(1): 173. CrossRef
Classification of the Stages of Nonalcoholic Steatohepatitis via Federated General Visual Representation Learning Mehmet Nergiz International Journal of Imaging Systems and Technology.2024;[Epub] CrossRef
Outcome prediction in metabolic dysfunction‐associated steatotic liver disease using stain‐free digital pathological assessment Timothy J. Kendall, Elaine Chng, Yayun Ren, Dean Tai, Gideon Ho, Jonathan A. Fallowfield Liver International.2024; 44(10): 2511. CrossRef
Chronic polypharmacy, monotherapy, and deprescribing: Understanding complex effects on the hepatic proteome of aging mice Kevin Winardi, John Mach, Matthew J. McKay, Mark P. Molloy, Sarah J. Mitchell, Michael R. MacArthur, Catriona McKenzie, David G. Le Couteur, Sarah N. Hilmer Aging Cell.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun BMC Gastroenterology.2023;[Epub] CrossRef
Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis Yoshihisa Takahashi, Erdenetsogt Dungubat, Hiroyuki Kusano, Toshio Fukusato Computational and Structural Biotechnology Journal.2023; 21: 2495. CrossRef
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease Timothy J. Kendall, Maria Jimenez-Ramos, Frances Turner, Prakash Ramachandran, Jessica Minnier, Michael D. McColgan, Masood Alam, Harriet Ellis, Donald R. Dunbar, Gabriele Kohnen, Prakash Konanahalli, Karin A. Oien, Lucia Bandiera, Filippo Menolascina, An Nature Medicine.2023; 29(11): 2939. CrossRef
Improved pathology reporting in NAFLD/NASH for clinical trials Caitlin Rose Langford, Marc H Goldinger, Darren Treanor, Clare McGenity, Jonathan R Dillman, Daniela S Allende, Robert Goldin, Elizabeth M Brunt, Kurt Zatloukal, Helmut Denk, Kenneth A Fleming Journal of Clinical Pathology.2022; 75(2): 73. CrossRef
Standardizing the histological assessment of late posttransplantation biopsies from pediatric liver allograft recipients Stefan G. Hübscher, Sandy Feng, Annette S. H. Gouw, Hironori Haga, Hyo Jeong Kang, Deirdre A. Kelly, Mina Komuta, Andrew Lesniak, Benjamin A. Popp, Henkjan J. Verkade, Eunsil Yu, Anthony J. Demetris Liver Transplantation.2022; 28(9): 1475. CrossRef
Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros Metabolism.2020; 104: 154144. CrossRef
A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy Kyoungbun Lee, Eun Sun Jung, Eunsil Yu, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Woo Sung Moon, Jin Sook Jeong, Cheol Keun Park, Jae-Bok Park, Dae Young Kang, Jin Hee Sohn, So-Young Jin Journal of Pathology and Translational Medicine.2020; 54(3): 228. CrossRef
An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Wei-Qiang Leow, Pierre Bedossa, Feng Liu, Lai Wei, Kiat-Hon Lim, Wei-Keat Wan, Yayun Ren, Jason Pik-Eu Chang, Chee-Kiat Tan, Aileen Wee, George Boon-Bee Goh Diagnostics.2020; 10(9): 643. CrossRef
Deep learning quantification of percent steatosis in donor liver biopsy frozen sections Lulu Sun, Jon N. Marsh, Matthew K. Matlock, Ling Chen, Joseph P. Gaut, Elizabeth M. Brunt, S. Joshua Swamidass, Ta-Chiang Liu EBioMedicine.2020; 60: 103029. CrossRef
Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease Juan S. Calle-Toro, Suraj D. Serai, Erum A. Hartung, David J. Goldberg, Bradley D. Bolster, Kassa Darge, Sudha A. Anupindi Abdominal Radiology.2019; 44(3): 894. CrossRef
R2 relaxometry based MR imaging for estimation of liver iron content: A comparison between two methods Juan S. Calle-Toro, Christian A. Barrera, Dmitry Khrichenko, Hansel J. Otero, Suraj D. Serai Abdominal Radiology.2019; 44(9): 3058. CrossRef
Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis Bernard Fromenty Liver Research.2019; 3(3-4): 157. CrossRef
Standardising the interpretation of liver biopsies in non‐alcoholic fatty liver disease clinical trials Rish K. Pai, David E. Kleiner, John Hart, Oyedele A. Adeyi, Andrew D. Clouston, Cynthia A. Behling, Dhanpat Jain, Sanjay Kakar, Mayur Brahmania, Lawrence Burgart, Kenneth P. Batts, Mark A. Valasek, Michael S. Torbenson, Maha Guindi, Hanlin L. Wang, Veeral Alimentary Pharmacology & Therapeutics.2019; 50(10): 1100. CrossRef
NAFLD Histology: a Critical Review and Comparison of Scoring Systems Rish K. Pai Current Hepatology Reports.2019; 18(4): 473. CrossRef
Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis Michael Estep, Rohini Mehta, Gary Bratthauer, Lakshmi Alaparthi, Fanny Monge, Simon Ali, Dinan Abdelatif, Zahra Younoszai, Maria Stepanova, Zachary D. Goodman, Zobair M. Younossi BMC Gastroenterology.2019;[Epub] CrossRef
Validation of intimate correlation between visceral fat and hepatic steatosis: Quantitative measurement techniques using CT for area of fat and MR for hepatic steatosis Moon Hyung Choi, Joon-Il Choi, Michael Yong Park, Sung Eun Rha, Soon Nam Oh, Seung Eun Jung, Jae Young Byun, Stephan Kannengiesser, Yohan Son Clinical Nutrition.2018; 37(1): 214. CrossRef
Ultrasound or MR elastography of liver: which one shall I use? Meng Yin, Sudhakar K. Venkatesh Abdominal Radiology.2018; 43(7): 1546. CrossRef
Feasibility and agreement of stiffness measurements using gradient-echo and spin-echo MR elastography sequences in unselected patients undergoing liver MRI Guilherme Moura Cunha, Kevin J Glaser, Anke Bergman, Rodrigo P Luz, Eduardo H de Figueiredo, Flavia Paiva Proença Lobo Lopes The British Journal of Radiology.2018; : 20180126. CrossRef
Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease Pik Eu Chang, George Boon Bee Goh, Wei Qiang Leow, Liang Shen, Kiat Hon Lim, Chee Kiat Tan, Manlio Vinciguerra PLOS ONE.2018; 13(6): e0199166. CrossRef